IP Library Granted Patent US 10,201,577
Granted Patent B2
US 10,201,577 · App. 15/431,833 · Granted Feb 12, 2019

Compositions and methods for enhancing working and long-term memory support using new combination of ginkgo biloba and panax ginseng and associated components

Inventor: Scott Eibel (Tampa, FL)
Assignee: KEYVIEW LABS, INC.
A61K36/258A23L33/105A23L33/15A61K9/0053A61K9/48A61K31/4415A61K31/519A61K31/714A61K36/16A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,577
App. No.
15/431,833
Granted
Feb 12, 2019
Kind
B2
Abstract

A nutritional supplement composition and associated method enhances working and long term memory support in a healthy adult person, and includes a Panax Ginseng extract and Ginkgo Biloba extract in a ratio a:b, wherein a for the Panax Ginseng extract is between about 1.9 and 2.8 and b for the Ginkgo Biloba extract is between bout 0.8 and 1.1. It is formulated for oral administration such that the Panax Ginseng extract and Ginkgo Biloba extract together account for at least 90 wt % of a dosage unit of the nutritional supplement composition. The Panax Ginseng extract and Ginkgo Biloba extract together may be present in the amount from about 320 mg to 960 mg. The dosage unit of the composition may be equal to or less than about 1,000 mg.

Claims (10)

1. A method for enhancing working and long term memory support in a healthy adult person comprising:

administering a nutritional supplement composition that includes a Panax Ginseng extract and Ginkgo Biloba extract, wherein said Panax Ginseng extract comprises at least 4% ginsenosides and the Ginkgo biloba extract comprises a leaf extract comprising about 24% glycosides and 6% terpenes, and the ginsenosides are in the amount of at least 10 mg and are at least 8.3% by weight of the amount by weight of the Ginkgo biloba extract, and the Panax Ginseng extract is at least 250 mg and the Ginkgo biloba extract is at least 120 mg; and

formulating the nutritional supplement composition for oral administration in a single dosage capsule such that the Panax Ginseng extract and Ginkgo Biloba extract together account for at least 90 wt % of a dosage unit of the nutritional supplement composition.

2. The method according to claim 1 wherein the Ginkgo Biloba extract is present in the amount up to about 150 mg.

3. The method according to claim 2 wherein the Ginkgo Biloba extract is present in the amount of about 120 mg.

4. The method according to claim 1 wherein the Panax Ginseng extract is present in the amount up to about 500 mg.

5. The method according to claim 4 wherein the Panax Ginseng extract is present in the amount of about 250 mg.

6. A method for enhancing working and long term memory support in a healthy adult person comprising:

administering a nutritional supplement composition that comprises a Panax Ginseng extract and Ginkgo Biloba extract, wherein said Panax Ginseng extract comprises at least about 4% ginsenosides and the Ginkgo biloba extract comprises a leaf extract comprising about 24% glycosides and 6% terpenes, and the ginsenosides are in the amount of at least 10 mg and are at least 8.3% by weight of the amount of Ginkgo biloba extract, and the Panax Ginseng extract is about 250 mg and the Ginkgo biloba extract is about 120 mg; and

formulating the nutritional supplement composition for oral administration into a single dosage capsule such that the Panax Ginseng extract and Ginkgo Biloba extract together account for at least 95 wt % of a dosage unit of the nutritional supplement composition.

Assignments (2)
SECURITY INTEREST Recorded Mar 15, 2021
From: KEYVIEW LABS, INC.
To: PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK)
Reel/Frame 055593/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2017
From: EIBEL, SCOTT
To: KEYVIEW LABS, INC.
Reel/Frame 041593/0326 →
Continuity (1)
Related Publication 20180228855A1 · Aug 16, 2018